Why are stem cell transplants carried out? white blood cells – which help fight infectionĪ stem cell transplant involves destroying any unhealthy blood cells and replacing them with stem cells removed from the blood or bone marrow.red blood cells – which carry oxygen around the body.The 3 main types of blood cell they can become are: Stem cells are special cells produced by bone marrow (a spongy tissue found in the centre of some bones) that can turn into different types of blood cells. It can be used to treat conditions affecting the blood cells, such as leukaemia and lymphoma. All rights reserved.A stem cell or bone marrow transplant replaces damaged blood cells with healthy ones. AML relapse after alloHCT predicted poor survival however, patients who relapsed ≥6 months after their initial alloHCT had better survival and may benefit from intensive therapy, such as second alloHCT ± DLI.Īcute myeloid leukemia Allogeneic transplantation Donor lymphocyte infusion Relapse Second transplantation.Ĭopyright © 2015 American Society for Blood and Marrow Transplantation. 0008), and use of cord blood for first HCT (relative risk, 1.23 95% CI, 1.06 to 1.42 P =. 0001), active graft-versus-host disease at relapse (relative risk, 1.25 95% CI, 1.13 to 1.39 P <. Median follow-up after relapse was 39 months (range, 40 years (relative risk, 1.42 95% CI, 1.24 to 1.64 P <. At relapse, 1231 patients (69%) received intensive therapy, including chemotherapy alone (n = 660), donor lymphocyte infusion (DLI) ± chemotherapy (n = 202), or second alloHCT ± chemotherapy ± DLI (n = 369), with subsequent CR rates of 29%. Median time to post-HCT relapse was 7 months (range, 1 to 177). We studied outcomes of 1788 AML patients relapsing after alloHCT (1990 to 2010) during first or second complete remission (CR) to identify factors associated with longer postrelapse survival. 8 Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.Īcute myeloid leukemia (AML) relapse after allogeneic hematopoietic cell transplantation (alloHCT) remains a major therapeutic challenge.7 Department of Internal Medicine III, Universitätsklinikum Ulm, Ulm, Germany.6 Department of Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio.5 Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center - James, Columbus, Ohio.4 Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.3 Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.Electronic address: 2 Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota. 1 Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |